Diagnosis and treatment of multiple myeloma in Hunan Province.

Feiyang Liu, Qian Cheng, Kui Song, Huan Yu, Junjun Li, Hui Zhang, Guoyu Hu, Ming Zhou, Jun Wang, Zhongqi Ding, Zimian Luo, Ting Peng, Liang Ding, Liang Zhao, Jing Liu, Yanjuan He, Hongling PengPubMed 2022 · DOI

Abstract

In 2019, the missed diagnosis rate of MM patients was high, the medium age of diagnosis was older, and the accuracy of patient diagnosis was not high. There is a great difference among medical centers, especially in the stage and risk stratified, nearly half of NDMM patients are not diagnosed with R-ISS stage; the lack of cytogenetic data needs to be supplemented by follow-up studies. A high proportion of patients with NDMM present with bone pain and anemia.Patients received treatment have higher use of chemotherapy regimens containing proteasome inhibitors and/or immunomodulators, but there is a significant gap among different medical centers, and standardized treatment needs to be strengthened. The safety during chemotherapy is controllable.
BibTeX
@inproceedings{liu2022diagnosis,
  author = {Feiyang Liu and Qian Cheng and Kui Song and Huan Yu and Junjun Li and Hui Zhang and Guoyu Hu and Ming Zhou and Jun Wang and Zhongqi Ding and Zimian Luo and Ting Peng and Liang Ding and Liang Zhao and Jing Liu and Yanjuan He and Hongling Peng},
  title = {{Diagnosis and treatment of multiple myeloma in Hunan Province.}},
  booktitle = {PubMed},
  year = {2022},
  doi = {10.11817/j.issn.1672-7347.2022.210555},
}

Loading related content...

Figure